Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults

Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00210-4/fulltext?dgcid=hubspot_update_feature_updatealerts_laninf&utm_campaign=update-laninf&utm_medium=email&_hsmi=277754630&_hsenc=p2ANqtz--exIbYoIujYDBGjQ3Zyh8g6H1G6V3i8GOwhPifGbcyxs4TzMubWhqJjxvNocrRHMWbFdHJPPX_d4z4Pos_lchpsAadyg&utm_content=277686900&utm_source=hs_email Oct 2023 Volume 23Number 10p1095-1206, e390-e454 The therapeutic validation of long COVID Jeremy Samuel Faust https://www.thelancet.com/journals/laninf/issue/vol23no10/PIIS1473-3099(23)X0010-3 Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00213-X/fulltext?dgcid=hubspot_update_feature_updatealerts_laninf&utm_campaign=update-laninf&utm_medium=email&_hsmi=277754630&_hsenc=p2ANqtz-8gtBKdNfT_6nER2DBFpk--ezW9-PXFAdJqefDO-_XJ-XO5ZcxiLLZBxPlFHGOxR5CLhqtrIycbn8lqm076cHw4fIttIw&utm_content=277686900&utm_source=hs_email